Peter Heutink - Alector Chief Officer
| ALEC Stock | USD 2.55 0.02 0.78% |
Insider
Peter Heutink is Chief Officer of Alector
| Address | 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | 415 231 5660 |
| Web | https://www.alector.com |
Alector Management Efficiency
The company has return on total asset (ROA) of (0.1925) % which means that it has lost $0.1925 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1255) %, meaning that it created substantial loss on money invested by shareholders. Alector's management efficiency ratios could be used to measure how well Alector manages its routine affairs as well as how well it operates its assets and liabilities. As of November 28, 2024, Return On Tangible Assets is expected to decline to -0.22. In addition to that, Return On Capital Employed is expected to decline to -0.36. At present, Alector's Other Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 17.8 M, whereas Total Assets are forecasted to decline to about 513.3 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| John Castle | Monte Rosa Therapeutics | 53 | |
| Path FRCP | Revolution Medicines | 61 | |
| JD Esq | Black Diamond Therapeutics | 59 | |
| Melanie Morrison | Black Diamond Therapeutics | 49 | |
| Kevan Shokat | Revolution Medicines | N/A | |
| Isabel Aznarez | Stoke Therapeutics | 52 | |
| Joan Wood | Stoke Therapeutics | N/A | |
| Elizabeth Buck | Black Diamond Therapeutics | 49 | |
| Mark MD | Passage Bio | 60 | |
| MSc MBA | Passage Bio | 55 | |
| Eric Rojas | Stoke Therapeutics | N/A | |
| JD MBA | Monte Rosa Therapeutics | 46 | |
| Anup MBA | Cabaletta Bio | 46 | |
| Nancy Ruiz | Larimar Therapeutics | N/A | |
| Phil JD | Monte Rosa Therapeutics | 45 | |
| TaiAn Lin | Black Diamond Therapeutics | N/A | |
| Desiree DDS | Passage Bio | N/A | |
| Ajim CFA | Monte Rosa Therapeutics | 47 | |
| Walter Reiher | Revolution Medicines | N/A | |
| Sharon Townson | Monte Rosa Therapeutics | 49 | |
| Samik MD | Cabaletta Bio | N/A | |
Management Performance
| Return On Equity | -1.13 | ||||
| Return On Asset | -0.19 |
Alector Leadership Team
Elected by the shareholders, the Alector's board of directors comprises two types of representatives: Alector inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alector. The board's role is to monitor Alector's management team and ensure that shareholders' interests are well served. Alector's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alector's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tillman Gerngross, Chairman of the Board, Co-Founder | ||
| Arnon Rosenthal, President CEO, Co-Founder, Director | ||
| Virginia MBA, Chief Strategy | ||
| Norah Conway, Program Portfolio | ||
| Gary MD, Chief Officer | ||
| Katie Hogan, Senior Relations | ||
| Sara KenkareMitra, President Development | ||
| Marc MD, Chief Officer | ||
| Kristina MPH, Pharmacovigilance, Regulatory | ||
| Michelle Corral, VP Relations | ||
| MS MBA, Chief Officer | ||
| Peter Heutink, Chief Officer | ||
| Danielle JD, General Counsel | ||
| Clare MBA, Chief Officer | ||
| Calvin Yu, Vice President - Finance | ||
| Saraswati KenkareMitra, President Development | ||
| Erica Jefferson, VP Affairs |
Alector Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alector a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.13 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (2.58) % | ||||
| Operating Margin | (3.01) % | ||||
| Current Valuation | (170.88 M) | ||||
| Shares Outstanding | 97.93 M | ||||
| Shares Owned By Insiders | 10.08 % | ||||
| Shares Owned By Institutions | 86.07 % | ||||
| Number Of Shares Shorted | 4.02 M | ||||
| Price To Earning | 21.35 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Alector offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alector's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alector Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alector Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alector. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Alector Stock refer to our How to Trade Alector Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alector. If investors know Alector will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alector listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.86) | Earnings Share (1.71) | Revenue Per Share 0.661 | Quarterly Revenue Growth 0.684 | Return On Assets (0.19) |
The market value of Alector is measured differently than its book value, which is the value of Alector that is recorded on the company's balance sheet. Investors also form their own opinion of Alector's value that differs from its market value or its book value, called intrinsic value, which is Alector's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alector's market value can be influenced by many factors that don't directly affect Alector's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alector's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alector is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alector's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.